| scholarly article | Q13442814 |
| P2093 | author name string | Malmborg AS | |
| Lindblad A | |||
| Ljungberg B | |||
| Nilsson-Ehle I | |||
| Strandvik B | |||
| Hjelte L | |||
| Christensson BA | |||
| P2860 | cites work | Pharmacokinetics of ciprofloxacin in cystic fibrosis | Q33741046 |
| Theophylline disposition in cystic fibrosis | Q34713572 | ||
| GASTRIC SECRETION IN FEVER AND INFECTIOUS DISEASES. | Q35175257 | ||
| Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis | Q35575446 | ||
| Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients | Q35651376 | ||
| Pharmacokinetics of netilmicin in children with and without cystic fibrosis | Q35670652 | ||
| Role of interleukin-1 in the depression of liver drug metabolism by endotoxin | Q37014156 | ||
| Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance | Q39673276 | ||
| High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients | Q39686183 | ||
| Pharmacokinetics of cephalosporins in normal and septicemic rabbits | Q39850390 | ||
| Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature | Q39879907 | ||
| Pharmacokinetics and temperature | Q39948564 | ||
| Advancing age and acute infection influence the kinetics of ceftazidime | Q40780021 | ||
| Changes of pharmacokinetics of trimethoprim after pretreatment with streptococcal peptidoglycan | Q40811818 | ||
| The influence of pyrogen induced fever on absorption of sulpha drugs | Q40886320 | ||
| Gentamicin Sulfate Pharmacokinetics: Lower Levels of Gentamicin in Blood during Fever | Q40895066 | ||
| Iron absorption and pyrexia | Q40926872 | ||
| Pharmacokinetics of Methicillin in Patients with Cystic Fibrosis | Q41251178 | ||
| Premature Senescence in Cultured Skin Fibroblasts from Subjects with Cystic Fibrosis | Q41466427 | ||
| Decreased renal clearance of sodium in cystic fibrosis | Q41996785 | ||
| An overview of the pharmacology of intravenously administered ciprofloxacin | Q42218107 | ||
| Renal function in rats with essential fatty acid deficiency | Q44165904 | ||
| Aminoglycoside clearance in patients with cystic fibrosis | Q44379780 | ||
| Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. | Q51618614 | ||
| Bioavailability of oral antibiotics in cystic fibrosis | Q67018731 | ||
| Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis | Q67343336 | ||
| Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis | Q67928184 | ||
| Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis | Q68499164 | ||
| Transintestinal elimination of ciprofloxacin | Q68724514 | ||
| Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis | Q68955375 | ||
| Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis | Q68955379 | ||
| Tissue penetration and metabolism of ciprofloxacin | Q69009369 | ||
| Assay of ciprofloxacin and norfloxacin in serum and urine by high-performance liquid chromatography | Q69061494 | ||
| Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis | Q69220536 | ||
| Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance | Q69225121 | ||
| Influence of endotoxin on the distribution of cephalosporins in rabbits | Q69570745 | ||
| Effect on renal function of essential fatty acid supplementation in cystic fibrosis | Q69667574 | ||
| Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection | Q69671407 | ||
| Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis | Q70113968 | ||
| Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis | Q70195609 | ||
| Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate | Q70507387 | ||
| Cephalexin pharmacokinetics in patients with cystic fibrosis | Q70585820 | ||
| Renal function in cystic fibrosis with special reference to the renal sodium handling | Q70621685 | ||
| Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis | Q71001102 | ||
| Factors affecting bile flow in the rabbit and rat | Q73640138 | ||
| The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas | Q78970553 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 2512-2517 | |
| P577 | publication date | 1992-11-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients | |
| P478 | volume | 36 |
| Q91801588 | Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics |
| Q33681237 | Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs |
| Q77542491 | Drug disposition in cystic fibrosis |
| Q27004711 | Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis |
| Q24188313 | Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis |
| Q31925615 | Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations |
| Q38040734 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones |
| Q24202879 | Oral anti-pseudomonal antibiotics for cystic fibrosis |
| Q24243916 | Oral anti-pseudomonal antibiotics for cystic fibrosis |
| Q26471106 | Oral anti-pseudomonal antibiotics for cystic fibrosis |
| Q40829169 | Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. |
| Q33983611 | Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis |
| Q42790860 | Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis |
| Q38663357 | Uncertainty and variability in human exposure limits - a chemical-specific approach for ciprofloxacin and methotrexate. |
Search more.